Pmda - Pharmaceuticals and Medical Devices Agency
Menu
Close

Regulatory Science/The Science Board/Standard Development

The 4th Subcommittee on Genome Editing

Press Release

Date and Time: May 27, 2019 from 2pm to 4pm

Agenda / List of Handouts

Agenda
  1. Lecture and Exchange of Opinions on Genome Editing
    • What Should We Consider Off-target Mutation Risk in Ex Vivo and In Vivo Genome Editing Therapy? (Dr. Akitsu Hotta, Junior Associate Professor, Department of Clinical Applications, Center for iPS Cell Research and Application (CiRA), Kyoto University)
  2. Summary of the 2nd & 3rd Subcommittee WG on Genome Editing
  3. Others
List of Handouts
  • Document 1  Lecture Materials (Dr. Akitsu Hotta, Junior Associate Professor, Department of Clinical Applications, Center for iPS Cell Research and Application (CiRA), Kyoto University)
  • Document 2-1  Summary of the 2nd Subcommittee WG on Genome Editing
  • Document 2-2  Summary of the 2nd Subcommittee WG on Genome Editing (Summary of Exchange of Opinions)
  • Document 3-1  Summary of the 3rd Subcommittee WG on Genome Editing
  • Document 3-2  Summary of the 3rd Subcommittee WG on Genome Editing (Summary of Exchange of Opinions)
  • Document 4  Point to Consider of Quality and Safety of Therapeutic Products Using Genome Editing Technology (Draft)
  • Document 5  Extracted Issues from Document 4